NASDAQ-Listed Rare Disease Biotech Executive Sells Shares and Executes 'Zero-Interest' Convertible Bond Deal Simultaneously

PTC Therapeutics, Inc. (Nasdaq: PTCT) Chief Business Officer Eric Paulus sold a portion of his common stock at roughly $75 per share on June 10 under a pre-arranged Rule 10b5-1 trading plan. That same day, he also exercised stock options and immediately sold the acquired shares in the open market, yet his remaining common-share position stayed at approximately 73,000 shares, according to a Form 4 filing.

Separately, on June 15 the company priced a private placement of zero-coupon convertible senior notes due June 15, 2031, for a total principal amount of $500 million, raising about $486.8 million (approximately KRW 600 billion). PTC announced it plans to deploy roughly $328.8 million (around KRW 450 billion) of the proceeds to cash-purchase $222 million of its outstanding 1.5% convertible notes maturing in 2026.

Leveraging the overallotment option, PTC then increased the offering on June 18 to $550 million (approximately KRW 700 billion) in zero-coupon convertible notes and concurrently completed the $328.8 million repurchase of a portion of its 2026 notes. The new notes carry a conversion price set about 40% above the Nasdaq closing price, and, as detailed in an 8-K filing and press release, may be subject to early conversion or a call option if specified stock-price triggers are met before their June 15, 2031, maturity.

Headquartered in Warren, New Jersey, PTC Therapeutics develops treatments for rare and genetic diseases and is publicly traded on Nasdaq. The company’s portfolio includes commercial products—such as its spinal muscular atrophy therapy—and a pipeline of candidates in various stages of approval. Recent attention has focused on its central nervous system programs, including a Huntington’s disease candidate, and on key partnerships. Investors are watching how this new convertible-note issuance and early debt repayment will affect PTC’s medium- to long-term capital structure and funding for research and development.